Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors - Wikidata - wikimedia - TriplyDB

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

http://www.wikidata.org/entity/Q36949688

about

Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of action HIV-1 integrase inhibitor resistance and its clinical implications Current perspectives on HIV-1 antiretroviral drug resistance Novel therapeutic strategies targeting HIV integrase Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.The HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide element Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor Solution conformation and dynamics of the HIV-1 integrase core domain.Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.Resistance to integrase inhibitors.Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness Rapid screening of HIV reverse transcriptase and integrase inhibitors.Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Allosteric inhibitor development targeting HIV-1 integrase.In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2 Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study.Role of raltegravir in the management of HIV-1 infection.Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.HIV-1 antiretroviral drug therapy.Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.Switching between raltegravir resistance pathways analyzed by deep sequencing Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.Potential benefit of dolutegravir once daily: efficacy and safety.Genetic Analysis of HIV-1 Integrase Sequences from Treatment Naive Individuals in Northeastern South Africa.Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.

P2860

Q24316120-B4535E35-5093-41AD-9455-0CB2675C5908 Q24628743-66E2FA0C-E0B7-4968-BB06-80C10A546AA0 Q26852626-D5B0C1A4-02AC-47CB-BF07-6D8F788429B4 Q27003960-A5A3417E-A0EA-4AEC-A131-65755D2AC03F Q27665427-0DF82FBC-6A7C-4779-AD14-24C770A5CC64 Q27670616-BAC33EDA-6D3C-41F7-83A7-8F303642B4CC Q28484930-1C4E01FD-207F-4504-864D-767426CC76FC Q28533830-5192CA39-26A4-430E-8342-AB7642F42A92 Q28547968-D3A3208D-B9CB-4B7B-94F6-C93A6A51BD9F Q30429621-1EF26F27-1871-4B4D-862B-7CD730DC72EB Q33680234-11D84B02-2DE1-464E-B5C5-F8ACD2B2B33A Q33786815-D2D71512-B951-4B1B-8E4C-67BC818FDB64 Q33797858-EEDD024E-A5AC-4681-80BA-3D2A7C8AC21D Q33885382-CA662FD5-B184-4882-B96C-D3AB4F97221C Q33911400-2E03637C-D55C-4C59-92D2-F36AE60162E6 Q34059119-8D68277A-7A9D-417E-84EC-2E468198F6AD Q34059575-D24C800B-EC8E-4013-AFDC-C4BBC94ACEF1 Q34059896-41272EA6-8720-40A8-BCD2-05F8933B6AE4 Q34108775-5300681D-9E33-47F6-B802-AC674539DDC1 Q34148077-55E27534-6405-46FF-923C-0035641DF854 Q34193340-0DE0199F-5F6E-47C6-8D15-2C825CAEFC79 Q34245624-B9D7928C-FFB6-4819-9C84-5E1407B9B9AE Q34398159-29F5308A-3CAA-407E-ACB1-9D56A922B260 Q34489239-DC74DB58-6D62-4020-8898-7E91D40BB592 Q34520239-8A1F196C-92D1-4BD2-89B1-4AE8B4D0DD8A Q35046515-85E4DDA2-B85F-49B4-88C9-FF9F2823A7D8 Q35083423-571DF987-EC3C-4365-86DD-284404B2ED52 Q35540399-221F624C-BA05-4669-A404-5D4D4846CF69 Q35557318-FF0084E8-6ABD-443A-9DF0-91F77CF8526B Q35760170-16D713C3-1387-4630-B702-B0616408958A Q35853012-EE25FB2D-25F4-4F84-857C-A7E369BA30EC Q35944477-C5BE3BAF-ABD5-43DD-9750-08308C4820E6 Q36011436-49469197-8FEA-4419-B485-55622DD4484E Q36155580-B5C6817B-C567-433C-95BF-AA16028BEF84 Q36281109-8348A43F-E66F-4A8B-9BFB-613F5F77689C Q36603416-B994AB75-0023-4D02-B077-982A9424D06C Q36790317-E6388D67-988C-4AA4-9126-1CA21205B5BB Q36839676-DC84BC97-78DD-441F-AFF4-126074FDB834 Q37026630-77594C5E-10AA-4915-93B0-2853CDE0DF3C Q37124155-33520A52-2E51-4835-A8E4-F4841B7D0BBB

P2860

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

http://www.wikidata.org/entity/Q36949688

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Resistance mutations in human ...... range of integrase inhibitors

@en

type

label

Resistance mutations in human ...... range of integrase inhibitors

@en

prefLabel

Resistance mutations in human ...... range of integrase inhibitors

@en

P1433

Q36949688-FEDD629E-E20D-4D04-AE64-CCB4EBE7DD68

P1476

Q36949688-1EB73065-78B4-4C37-8DB4-628142A54379

P2093

Q36949688-0D83B684-AEF8-490C-96C4-D0180EA1090F

Q36949688-1ECD96FA-C6C6-4B10-ACF7-10CC31EC488E

Q36949688-241621EE-8383-4E73-9164-C46AF6B8540A

Q36949688-258F77D6-0DF4-4283-A753-D91438F18ECB

Q36949688-4175A67F-E2C4-44E7-9DD9-0B00112B173B

Q36949688-4F819237-F862-4D89-924D-72C518C55A8D

Q36949688-6504B4B6-CB4A-4EC9-A1CE-F5C1B06BFCCC

Q36949688-6E07F534-6664-425F-B77B-976ADBD06CB9

Q36949688-8419630A-B0F9-413F-B13D-539B1E7158AE

Q36949688-A5D5B876-84F0-4AA6-BF33-7AD6400014F2

P2860

Q36949688-0F03E68B-5944-4A0F-945B-FDF68EC7C947

Q36949688-11F241A6-7DD8-4F03-939F-6825D5434F50

Q36949688-24ACDC2B-DBEE-4D36-8FB0-696FC9344849

Q36949688-28AB0F49-2759-4520-A6E5-7C2945E6898C

Q36949688-3A787433-C1B2-489C-B157-BC95F920783A

Q36949688-41B23780-7562-42ED-BED9-CC89B6F8D591

Q36949688-56A2EC10-E62D-4B80-8A8F-51630EA1A1A5

Q36949688-5A3F59BE-577A-4829-8765-FC66A0FF8933

Q36949688-5E7060A5-5877-47E3-B0B1-1844F37E990C

Q36949688-62E9A3CA-2DE4-4B0C-90D6-93E297829594

P304

Q36949688-DD4F3C42-6C3C-4D4F-AE7B-06558F6831BD

P31

Q36949688-AE2B5275-A1E4-4659-BF22-D2A8FD409DB9

P356

Q36949688-C28ECF02-7B8B-490F-997A-1189C3671C7F

P407

Q36949688-195EFAA0-D415-4E98-9BF7-FF63B49172B8

P433

Q36949688-7B6EAB23-549D-4F94-B212-017CF4AA457F

P478

Q36949688-8BED030D-6CCC-46F8-9694-4EEF496FFA1C

P50

Q36949688-13952A26-2D11-40D0-AE76-5B56895B9D2A

Q36949688-22D6744B-1EBA-421A-9817-F1979461041A

Q36949688-492C1651-B2DB-4A53-AC1C-AD3BF453580F

Q36949688-ED16FAFF-4316-484B-8696-E890358A93DB

P577

Q36949688-6412CF11-12C1-47D6-833C-0EB7E9EB9AB4

P5875

Q36949688-F8225184-9E55-419B-A9FB-2DE5FD754406

P698

Q36949688-BFE78F1B-A354-4789-AA5B-A1CB9D59CB4A

P932

Q36949688-A66BFF03-3918-43EF-8116-B9181B20D906

P356

P1433

Journal of Virology

P1476

Resistance mutations in human ...... range of integrase inhibitors

@en

P2093

Elisabeth Wagemans

http://www.w3.org/2001/XMLSchema#string

Geert Meersseman

http://www.w3.org/2001/XMLSchema#string

Inge Vereycken

http://www.w3.org/2001/XMLSchema#string

Koen Dockx

http://www.w3.org/2001/XMLSchema#string

Kurt Hertogs

http://www.w3.org/2001/XMLSchema#string

Marcia Van Ginderen

http://www.w3.org/2001/XMLSchema#string

Olivia Goethals

http://www.w3.org/2001/XMLSchema#string

Peggy Geluykens

http://www.w3.org/2001/XMLSchema#string

Reginald Clayton

http://www.w3.org/2001/XMLSchema#string

Rudy Strijbos

http://www.w3.org/2001/XMLSchema#string

P2860

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity

Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

HIV integrase structure and function.

In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.

Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid

Integrase inhibitors to treat HIV/AIDS.

S-1360 Shionogi-GlaxoSmithKline.

Novel inhibitors of HIV-1 integration.

P304

10366-10374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.00470-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Schols

P577

2008-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23183129

http://www.w3.org/2001/XMLSchema#string

P698

18715920

http://www.w3.org/2001/XMLSchema#string

P932

2573211

http://www.w3.org/2001/XMLSchema#string